Novartis recently announced plans to add a new facility in Morrisville, North Carolina, focused on Active Pharmaceutical Ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics. The facility represents a critical step that will strengthen end?to?end US production capability from active ingredients through finished medicines.

This announcement marks the company’s seventh new facility planned within a year of its announced USD 23 billion investment in US-based manufacturing, research and development. The 56,200-square-foot facility will expand the company’s presence in North Carolina to five facilities across three sites. The infrastructure will support not only today’s medicines, but also the development and delivery of future innovative therapies for US patients.

Vas Narasimhan, CEO, Novartis, said, “Last year, we committed to adding seven new facilities in the US, and today we finalise our plans to expand our US manufacturing and R&D footprint in the US. By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale, enabling timely access to innovation for patients in the US.”

Since April 2025, Novartis has made significant progress on its commitment to manufacture all key Novartis medicines for US patients in the US. These investments are expanding capacity and building the foundation to deliver advanced therapies to the patients who rely on them, including time-sensitive treatments like radioligand therapies (RLT).

The company is on track to establish end-to?end manufacturing for all advanced technology platforms in the US, including small and large molecules, and radioligand, RNA therapeutics, cell and gene therapies—a first in Novartis history.